GO
Loading...

Acquisitions

More

  • LONDON, May 8- The European Commission would probably block any attempt by the British government to intervene in Pfizer's proposed takeover of AstraZeneca as Brussels itself would rule on a deal of that size, competition lawyers say. AstraZeneca has rejected the $106 billion bid to create the world's largest pharmaceuticals business.

  • May 8- Deal-making drugmaker Valeant Pharmaceuticals International Inc, together with activist investor Pershing Square, plan to push for changes on the board of Allergan Inc, which Valeant hopes to acquire.

  • BUSINESS-NEWS-SCHEDULE AT 1830 GMT / 2:30 PM ET Wednesday, 7 May 2014 | 2:42 PM ET

    British PM tells Pfizer wants more commitments for AstraZeneca deal. LONDON- Prime Minister David Cameron says Britain wants more commitments from Pfizer on its $106 billion takeover bid for British pharmaceutical company AstraZeneca.

  • *Cameron hints Britain could intervene in takeover deal. LONDON, May 7- Prime Minister David Cameron demanded U.S. drugmaker Pfizer give stronger guarantees it will keep jobs and investment in Britain in order to secure his government's blessing for a takeover of AstraZeneca.

  • Pfizer says AstraZeneca takeover would benefit science Wednesday, 7 May 2014 | 3:54 AM ET

    LONDON, May 7- Pfizer sought to allay fears that its proposed $106 billion takeover of AstraZeneca would deal a blow to drug research, saying the new company would bolster innovative science and speed the development of new treatments. AstraZeneca, Britain's second-largest drugs company, has rejected successive approaches from its larger American rival.

  • *UK could use public interest powers, Business Secretary says. *Lawmakers summon Pfizer, AstraZeneca bosses over takeover bid. LONDON, May 6- Britain could use its public interest powers to intervene in U.S. drugmaker Pfizer's $106- billion takeover bid for British pharmaceutical firm AstraZeneca, Business Secretary Vince Cable said on Tuesday.

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106- billion takeover approach on Tuesday by predicting its sales would rise by three quarters over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • LONDON, May 6- British lawmakers on Tuesday summoned bosses of U.S. drugmaker Pfizer to explain a $106 billion takeover bid for pharmaceutical firm AstraZeneca which has raised fears over UK jobs, research and intellectual property.

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106 billion takeover approach on Tuesday by predicting its revenues would rise 75 percent over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • LONDON, May 6- Senior management from U.S. drugmaker Pfizer and British pharmaceutical firm AstraZeneca will be called before a British parliamentary committee to answer questions on a potential takeover deal, the committee chairman said on Tuesday.

  • LONDON, May 6- Representatives from U.S. drugmaker Pfizer and British pharmaceutical firm AstraZeneca will be called before a British parliamentary committee to discuss a potential takeover deal in the coming weeks, a committee spokesman said on Tuesday.

  • AstraZeneca acquired drug after buying Omthera in 2013. LONDON, May 6- AstraZeneca Plc has won U.S. approval for Epanova, a new pill for heart disease, providing a welcome- but relatively minor- piece of good news as it fights a $106 billion takeover approach from Pfizer Inc.

  • NEW YORK, May 5- Pfizer Inc's top officials said on Monday they are weighing all strategies, including potential hostile maneuvers, in the company's effort to seal a $106 billion takeover of British drugmaker AstraZeneca Plc.

  • Oncor avoided bankruptcy because of a credit provisions called a ring-fence put in place in 2007 to satisfy Texas legislators and regulators worried about the $40 billion debt created in the leveraged buyout by a group of private equity firms led by KKR& Co LP.

  • SYDNEY, May 5- Australian gas firm WestSide Corp Ltd on Monday rejected as undervalued a takeover offer from China's diversified energy company Landbridge Group Co Ltd that valued the company at A $177.6 million.

  • LONDON, May 4- Britain should conduct an independent assessment of a potential takeover of British pharmaceutical firm AstraZeneca by U.S. drugmaker Pfizer, opposition Labour party leader Ed Miliband said on Sunday. AstraZeneca rejected a 63 billion pound takeover bid from Pfizer on Friday, but the U.S. firm is expected to pursue its interest.

  • Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.

  • May 3- Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal.

  • NEW YORK, May 3- Employees at Pfizer Inc's U.S. research centers, such as the La Jolla, California site that specializes in cancer drugs, may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.

  • May 2- Private equity firm Arsenal Capital Partners is considering a sale of its business that helps U.S. oil and chemical companies reclaim import taxes, a partner at the firm said. Charter, which has annual net revenue of about $65 million to $70 million, is the largest U.S. petroleum and chemical drawback services provider.